Confirming the SUCCESS of celecoxib in reducing GI complications

The cyclo-oxygenase-2 (COX-2) inhibitors, or 'coxibs', have rapidly carved out a place in the management of conditions requiring NSAID therapy, due to their superior gastrointestinal (GI) tolerability over conventional NSAIDs. Data from several studies presented during a session at Digestive Disease Week [Atlanta, US; May 2001], including the SUCCESS-I* in Osteoarthritis trial, provided confirmation of the positive results already seen with the COX-2 inhibitor celecoxib ['Celebrex'] in terms of the development of ulcer complications and symptomatic ulcers.